1. Home
  2. TYRA

as 06-20-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Founded: 2018 Country:
United States
United States
Employees: N/A City: CARLSBAD
Market Cap: 576.6M IPO Year: 2021
Target Price: $30.86 AVG Volume (30 days): 360.4K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.63 EPS Growth: N/A
52 Week Low/High: $6.42 - $29.60 Next Earning Date: 08-06-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

TYRA Daily Stock ML Predictions

Stock Insider Trading Activity of Tyra Biosciences Inc. (TYRA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
RA CAPITAL MANAGEMENT, L.P. TYRA Director10% Owner Jun 12 '25 Buy $10.18 163,287 $1,664,700.49 10,127,311
RA CAPITAL MANAGEMENT, L.P. TYRA Director10% Owner Jun 4 '25 Buy $9.84 1,211,198 $11,751,303.68 10,127,311

Share on Social Networks: